Jame Abraham, MD, on ER-Positive Breast Cancer: Expert Perspective on Initial Results of NRG Oncology/NSABP B-42
2016 San Antonio Breast Cancer Symposium
Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).
Virginia G. Kaklamani, MD, DSc, of The University of Texas Health Science Center, discusses new directions in prevention, early detection, and treatment of early-stage breast cancer, using genomic tests and targeted therapies.
Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).
Monica Morrow, MD, of Memorial Sloan Kettering Cancer Center, recognized at this year’s meeting for scientific distinction in clinical research, summarizes her Brinker Award lecture on modifying local therapy to decrease the burden of cancer treatment.
Stephen R.D. Johnston, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss the role of endocrine therapy and optimal sequencing, recent progress in first-line treatment, and resistance pathways and second-line treatment (Plenary Lecture 1).
Jennifer A. Ligibel, MD, of Harvard Medical School, discusses the impact of preoperative exercise on breast cancer gene expression (Abstract S5-05).